Dr. Reddy's Laboratories Ltd

RDY Healthcare Drug Manufacturers Specialty & Generic

Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025. In the quarter to June 2026, revenue fell 14.4%, EPS fell 70.0%, free cash flow fell 143.4% and total debt rose 34.0%, each against the same quarter a year earlier.

13.05 0.15 +1.16%
Market cap
$10.7B
P/E
32.9×
Fwd P/E
24.3×
Dividend yield
0.00%
F-score
4/9
Altman Z
5.26
Beneish M
−2.59
Dividend safety
74/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

17.45% 16.28% 11.40% 8.21%
Piotroski F-Score
3 4 4 5
ROA
11.62% 10.88% 7.63% 5.55%
ROIC
13.05% 11.88% 8.55% 5.89%
Return on Tangible Assets
25.02% 22.80% 17.09% 12.38%
Average Days of Receivables
101.85 106.53 110.01 112.81
Free Cash Flow per Share
0.26 0.35 0.26 0.18
Free Cash Flow
220.00 288.00 215.00 139.00
Other line items

Show all line items

Columns are period end dates